Brokerages Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Target Price at $25.71

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) has been given a consensus recommendation of “Moderate Buy” by the nine analysts that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $25.7143.

A number of research firms have commented on DAWN. Zacks Research upgraded Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a report on Monday, December 29th. Needham & Company LLC restated a “buy” rating and set a $16.00 price target on shares of Day One Biopharmaceuticals in a report on Monday, November 24th. Piper Sandler boosted their price target on shares of Day One Biopharmaceuticals from $25.00 to $26.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of Day One Biopharmaceuticals in a research report on Monday, November 24th.

Insiders Place Their Bets

In other news, insider Lauren Merendino sold 3,726 shares of Day One Biopharmaceuticals stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $8.91, for a total value of $33,198.66. Following the completion of the transaction, the insider directly owned 50,809 shares of the company’s stock, valued at approximately $452,708.19. This trade represents a 6.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Charles N. York II sold 4,062 shares of the business’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $8.91, for a total value of $36,192.42. Following the completion of the transaction, the chief financial officer directly owned 294,715 shares in the company, valued at $2,625,910.65. This represents a 1.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 28,001 shares of company stock valued at $249,489. 6.20% of the stock is currently owned by insiders.

Institutional Trading of Day One Biopharmaceuticals

Several large investors have recently modified their holdings of the stock. GC Wealth Management RIA LLC increased its stake in shares of Day One Biopharmaceuticals by 200.1% in the 4th quarter. GC Wealth Management RIA LLC now owns 150,030 shares of the company’s stock valued at $1,398,000 after acquiring an additional 100,030 shares in the last quarter. Pictet Asset Management Holding SA grew its holdings in Day One Biopharmaceuticals by 26.0% in the fourth quarter. Pictet Asset Management Holding SA now owns 2,990,801 shares of the company’s stock worth $27,874,000 after purchasing an additional 617,668 shares during the period. Vanguard Group Inc. increased its stake in Day One Biopharmaceuticals by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 6,282,376 shares of the company’s stock valued at $58,552,000 after purchasing an additional 101,047 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Day One Biopharmaceuticals by 59.9% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 38,520 shares of the company’s stock valued at $359,000 after purchasing an additional 14,425 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Day One Biopharmaceuticals by 26.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,989 shares of the company’s stock worth $46,000 after purchasing an additional 1,029 shares in the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Stock Performance

DAWN stock opened at $11.16 on Tuesday. The company has a market capitalization of $1.15 billion, a P/E ratio of -7.34 and a beta of -1.27. The company has a fifty day moving average price of $9.68 and a 200-day moving average price of $8.16. Day One Biopharmaceuticals has a 52-week low of $5.64 and a 52-week high of $13.20.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.09. The company had revenue of $39.80 million for the quarter, compared to analysts’ expectations of $38.20 million. Day One Biopharmaceuticals had a negative net margin of 113.53% and a negative return on equity of 32.05%. Day One Biopharmaceuticals’s revenue for the quarter was down 57.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.38 earnings per share. As a group, sell-side analysts forecast that Day One Biopharmaceuticals will post -0.72 earnings per share for the current fiscal year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.